First personalised cancer vaccine cuts risk of disease returning in major trial

In the trial, 1,137 adults were given Keytruda, an established immunotherapy drug which helps the body's immune system find and attack cancer cells.

The vaccine, called Intismeran, uses the same mRNA technology as some Covid jabs.

It is personalised to each patient, using information from their own tumour to help train their immune system to recognise cancer cells and target them if they return.

Two years after starting the treatment, the patients who received the jab were far less likely to have had melanoma come back or see it spread across the body.

"Personalisation is the next step up and it's really exciting, it's a fabulous technology," says Prof Pippa Corrie, a consultant medical oncologist who helped run part of the study with patients at Addenbrooke's Hospital in Cambridge.

Shares in the drugmakers MSD (known as Merck in the US) and Moderna have surged since both companies first hinted at the success of the vaccine in the summer.

But investors sold off stock on Thursday after financial analysts said the results were not quite as strong as those seen in an earlier, much smaller trial.

Widespread NHS use will also depend on cost, given that each individual patient will need to have their tumour genetically analysed and a personalised vaccine made for them.

The trial will continue so that the patients involved can be monitored – both to see if the cancer returns over time and to assess whether the drug ultimately helps them live longer.

"It is an important proof of principle for the field, although we shouldn't get ahead of the evidence," he said.

"We can't assume from one melanoma trial that the same approach will work across all cancers, and longer follow-up will be important to understand the effect on overall survival."

They have yet to be published in a peer-reviewed medical journal, where they can be scrutinised by independent experts.